获得性囊性肾病相关肾细胞癌的研究进展

doi:10.3969/j.issn.1674-8115.2022.05.018

上海交通大学学报（医学版） ›› 2022, Vol. 42 ›› Issue (5): 680-684.doi: 10.3969/j.issn.1674-8115.2022.05.018

获得性囊性肾病相关肾细胞癌的研究进展

向晗¹(), 向武², 张伟国¹()

^1.陆军军医大学大坪医院放射科，重庆 400042
^2.重庆市北碚区中医院康复科，重庆 400799

收稿日期:2022-01-17 接受日期:2022-04-18 出版日期:2022-05-28 发布日期:2022-05-28
通讯作者: 张伟国 E-mail:903274184@qq.com;wgzhang01@163.com
作者简介:向晗（1995—），女，硕士生；电子信箱：903274184@qq.com。
基金资助:
重庆市影像医学与核医学临床研究中心项目(CSTC2015YFPT-gcjsyjzx0175)

Research progress in acquired cystic disease-associated renal cell carcinoma

XIANG Han¹(), XIANG Wu², ZHANG Weiguo¹()

^1.Department of Radiology, Daping Hospital, Army Medical University, Chongqing 400042, China
^2.Department of Rehabilitation, Chongqing Beibei Traditional Chinese Medical Hospital, Chongqing 400799, China

Received:2022-01-17 Accepted:2022-04-18 Online:2022-05-28 Published:2022-05-28
Contact: ZHANG Weiguo E-mail:903274184@qq.com;wgzhang01@163.com
Supported by:
Fund of Chongqing Clinical Research Centre of Imaging and Nuclear Medicine(CSTC2015YFPT-gcjsyjzx0175)

摘要/Abstract

摘要：

获得性囊性肾病相关肾细胞癌（acquired cystic disease-associated renal cell carcinoma，ACD-RCC）是终末期肾病及获得性囊性肾病患者最常见的肾脏肿瘤类型，2016年作为一种新的肾癌亚型纳入世界卫生组织肾脏肿瘤分类中。虽然该病是一种低度恶性肿瘤，但也可能出现局部复发或远处转移。对于长期透析尤其是并发症少的年轻患者，应定期行影像学监测，早期发现病变，早期干预，改善患者预后，提高其生存质量。目前，国内外文献主要聚焦在其临床病理方面，对该病影像特征、预后及监测方面的研究有限。该文归纳总结了ACD-RCC的流行病学特征、病因、病理特征、影像表现、治疗方法、预后及监测方法，旨在帮助临床医师更全面地认识ACD-RCC，为ACD-RCC的诊疗及监测提供参考。

关键词: 获得性囊性肾病, 肾细胞癌, 影像特征, 预后

Abstract:

Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is the most common type of RCC seen in patients with end-stage renal disease and acquired cystic kidney disease, and was added to the list of RCC subtypes in the 2016 World Health Organization classification. ACD-RCC is generally believed to be indolent, however, some tumors may show local recurrence and distant metastasis. Periodic screening should be performed in dialysis patients, especially in younger patients with minor comorbidities, early detection and early intervention can improve the prognosis and quality of life. Literatures published at home and abroad mainly focused on it's clinicopathological features, there is scarce research describing the imaging appearance, prognosis and surveillance of ACD-RCC. This paper summarizes the epidemiology, etiology, pathological features, imaging manifestations, treatment, prognosis and surveillance of ACD-RCC, and aims to provide a compressive understanding of the disease for clinicians.

Key words: acquired cystic disease, renal cell carcinoma, image features, prognosis

中图分类号:

R737.11

向晗, 向武, 张伟国. 获得性囊性肾病相关肾细胞癌的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(5): 680-684.

XIANG Han, XIANG Wu, ZHANG Weiguo. Research progress in acquired cystic disease-associated renal cell carcinoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 680-684.

参考文献 34

1	TICKOO S K, DEPERALTA-VENTURINA M N, HARIK L R, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia[J]. Am J Surg Pathol, 2006, 30(2): 141-153.
2	PRZYBYCIN C G, HARPER H L, REYNOLDS J P, et al. Acquired cystic disease-associated renal cell carcinoma (ACD-RCC): a multiinstitutional study of 40 cases with clinical follow-up[J]. Am J Surg Pathol, 2018, 42(9): 1156-1165.
3	MOCH H, CUBILLA A L, HUMPHREY P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105.
4	INAMURA K. Renal cell tumors: understanding their molecular pathological epidemiology and the 2016 WHO classification[J]. Int J Mol Sci, 2017, 18(10): E2195.
5	FOSHAT M, EYZAGUIRRE E. Acquired cystic disease-associated renal cell carcinoma: review of pathogenesis, morphology, ancillary tests, and clinical features[J]. Arch Pathol Lab Med, 2017, 141(4): 600-606.
6	ISHIHARA H, YAMASHITA S, LIU Y Y, et al. Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease[J]. Cancer Sci, 2020, 111(11): 4276-4287.
7	MEOLA M, SAMONI S, PETRUCCI I. Clinical scenarios in chronic kidney disease: kidneys' structural changes in end-stage renal disease[J]. Contrib Nephrol, 2016, 188: 131-143.
8	KALIL R S, LYNCH C F, ENGELS E A. Risk of cancer in retransplants compared to primary kidney transplants in the United States[J]. Clin Transplant, 2015, 29(10): 944-950.
9	TSUZUKI T, IWATA H, MURASE Y, et al. Renal tumors in end-stage renal disease: a comprehensive review[J]. Int J Urol, 2018, 25(9): 780-786.
10	SHAH A, LAL P, TOORENS E, et al. Acquired cystic kidney disease-associated renal cell in KMT2C and TSC2 genes[J]. Am J Surg Pathol, 2020, 44(11): 1479-1486.
11	FUSHIMI F, TAGUCHI K, IZUMI H, et al. Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma[J]. Virchows Arch, 2013, 463(4): 553-562.
12	HORI Y, ODA Y, KIYOSHIMA K, et al. Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis[J]. J Pathol, 2007, 212(2): 218-226.
13	TOYOKUNI S. The origin and future of oxidative stress pathology: from the recognition of carcinogenesis as an iron addiction with ferroptosis-resistance to non-thermal plasma therapy[J]. Pathol Int, 2016, 66(5): 245-259.
14	CHEN T T, ACHAN A, WONG G. Acquired cystic disease-associated renal cell carcinoma[J]. Nephrology (Carlton), 2018, 23(7): 704-705.
15	KOJIMA F, GANDHI J S, MATSUZAKI I, et al. Comprehensive clinicopathologic analyses of acquired cystic disease-associated renal cell carcinoma with focus on adverse prognostic factors and metastatic lesions[J]. Am J Surg Pathol, 2020, 44(8): 1031-1039.
16	KURODA N, TAMURA M, HAMAGUCHI N, et al. Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features[J]. Ann Diagn Pathol, 2011, 15(6): 462-466.
17	SRIGLEY J R, DELAHUNT B, EBLE J N, et al. The international society of urological pathology (ISUP) Vancouver classification of renal neoplasia[J]. Am J Surg Pathol, 2013, 37(10): 1469-1489.
18	KURODA N, YAMASHITA M, KAKEHI Y, et al. Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study[J]. Med Mol Morphol, 2011, 44(4): 228-232.
19	CHRABAŃSKA M, JAKUB R, BOGNA D. Bilateral and multifocal acquired cystic disease–associated renal cell carcinomas in patient with end-stage renal disease caused by systemic lupus erythematosus[J]. Int J Surg Pathol, 2021, 29(2): 198-204.
20	KATABATHINA V S, GARG D, PRASAD S R, et al. Cystic renal neoplasms and renal neoplasms associated with cystic renal diseases in adults: cross-sectional imaging findings[J]. J Comput Assist Tomogr, 2012, 36(6): 659-668.
21	EDO H, SUYAMA Y, SUGIURA H, et al. Acquired cystic disease-associated renal cell carcinoma extending to the renal pelvis mimicking urothelial carcinoma on computed tomography (CT): two case reports[J]. Am J Case Rep, 2020, 21: e926630.
22	BERKENBLIT R, RICCI Z, KANMANIRAJA D, et al. CT features of acquired cystic kidney disease-associated renal cell carcinoma[J]. Clin Imaging, 2022, 83: 83-86.
23	KITAJIMA K, YAMAMOTO S, KAWANAKA Y, et al. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison ¹¹C-choline and FDG PET/CT with dynamic contrast-enhanced CT[J]. Jpn J Radiol, 2019, 37(2): 165-177.
24	AKITA H, JINZAKI M, AKITA A, et al. Renal cell carcinoma in patients with acquired cystic disease of the kidney: assessment using a combination of T2-weighted, diffusion-weighted, and chemical-shift MRI without the use of contrast material[J]. J Magn Reson Imaging, 2014, 39(4): 924-930.
25	KIM S Y, WOO S, HWANG S I, et al. Usefulness of resistive index on spectral Doppler ultrasonography in the detection of renal cell carcinoma in patients with end-stage renal disease[J]. Ultrasonography, 2014, 33(2): 136-142.
26	LEE S H, PARK J S, KIM H, et al. Glycolysis on F-18 FDG PET/CT is superior to amino acid metabolism on C-11 methionine PET/CT in identifying advanced renal cell carcinoma at staging[J]. Cancers (Basel), 2021, 13(10): 2381.
27	CIMADAMORE A, CHENG L, SCARPELLI M, et al. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review[J]. Transl Androl Urol, 2021, 10(3): 1506-1520.
28	ROBILA V, KRAFT A O, SMITH S C. New entities, new technologies, new findings: a review of the cytologic features of recently established subtypes of renal cell carcinoma[J]. Cancer Cytopathol, 2019, 127(2): 79-97.
29	KURODA N, NARODA T, TAMURA M, et al. Acquired cystic disease-associated renal cell carcinoma: a clinicopathological study of seven cases[J]. Pol J Pathol, 2017, 68(4): 306-311.
30	BUTUROVIĆ-PONIKVAR J, VISNAR-PEROVIC A. Ultrasonography in chronic renal failure[J]. Eur J Radiol, 2003, 46(2): 115-122.
31	MEOLA M, PETRUCCI I. Ultrasound and color Doppler applications in chronic kidney disease[J]. G Ital Nefrol, 2012, 29(6): 699-715.
32	SIDHU P S, CANTISANI V, DIETRICH C F, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version)[J]. Ultraschall Med, 2018, 39(2): e2-e44.
33	LIAKOPOULOS V, ELEFTHERIADIS T, MERTENS P R. Screening for renal cell carcinoma in dialysis patients[J]. Kidney Int, 2018, 94(6): 1238.
34	DAHLE D O, SKAUBY M, LANGBERG C W, et al. Renal cell carcinoma and kidney transplantation: a narrative review[J]. Transplantation, 2022, 106(1): e52-e63.

[1]	朱田雨, 宗春燕, 许诗琼, 葛盛芳, 范先群, 贾仁兵. 结膜黑色素瘤组织病理学特征、Ki-67表达和预后的关系[J]. 上海交通大学学报（医学版）, 2022, 42(5): 617-623.
[2]	邢正文, 吴滢, 王雪莉, 王庆煜, 王文婷, 李治, 张彬, 金晶. 8例儿童卵巢颗粒细胞瘤临床病理特征及预后分析[J]. 上海交通大学学报(医学版), 2022, 42(2): 192-196.
[3]	陆雪梅, 陈兰. 改良危重症营养风险评分在老年危重症患者中的应用[J]. 上海交通大学学报(医学版), 2022, 42(1): 16-20.
[4]	宣贝贝, 龚赛楠, 刘佳丽, 全权, 孟雨, 牟晓玲. DNA聚合酶θ在子宫内膜癌中的表达及其临床意义[J]. 上海交通大学学报(医学版), 2021, 41(9): 1207-1214.
[5]	熊雷, 易茜, 许明芳, 陈健. MRPL12在肺腺癌中的表达和预后分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1033-1040.
[6]	周珺珺, 赵洁, 汤静燕, 蒋马伟, 马秀梅, 白永瑞. Ⅲ~Ⅳ期神经母细胞瘤患儿放射治疗预后因素分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1051-1055.
[7]	陈盛, 严志龙, 吴晔明, 徐敏, 顾松, 马靖. HIF-1α/SHH信号通路在神经母细胞瘤中的表达及临床意义[J]. 上海交通大学学报(医学版), 2021, 41(8): 1056-1061.
[8]	刘青, 张娜, 邵静波, 李红, 陈凯, 杜成坎, 王真, 蒋慧. MLL基因重排阳性的儿童急性白血病患者的临床特点及预后分析[J]. 上海交通大学学报(医学版), 2021, 41(7): 903-909.
[9]	程盛, 赵益, 王永琛, 黄平. BRAF基因突变对肝切除后的结直肠癌肝转移患者预后影响的meta分析[J]. 上海交通大学学报(医学版), 2021, 41(6): 786-792.
[10]	陈旭光, 施晟懿, 胡岚, 陈瑜, 陆一鸣, 叶静. 血浆纤维蛋白降解产物对出血性脑卒中患者早期预后的评估价值[J]. 上海交通大学学报(医学版), 2021, 41(5): 612-616.
[11]	包汝娟, 陈慧芳, 董宇, 叶幼琼, 苏冰. 基于转录组异常表达构建结直肠癌特征基因预后风险评分模型[J]. 上海交通大学学报(医学版), 2021, 41(3): 285-296.
[12]	马燕如, 季林华, 童天颖, 严宇青, 沈超琴, 张昕雨, 曹颖颖, 洪洁, 陈豪燕. 基于单细胞RNA测序的结直肠癌预后预测模型的建立和验证[J]. 上海交通大学学报(医学版), 2021, 41(2): 159-165.
[13]	胡培堃, 何杰, 吴连明, 葛恒, 许建荣, 卜军. ST段抬高型心肌梗死患者微血管阻塞对左室功能及预后的影响[J]. 上海交通大学学报(医学版), 2021, 41(2): 173-179.
[14]	傅中懋, 罗再, 戎泽印, 章建明, 李腾飞, 余志龙, 黄陈. 基于高通量测序的结直肠癌组织中环状RNA功能研究与预后分析[J]. 上海交通大学学报(医学版), 2021, 41(2): 187-195.
[15]	张珠晟, 刘琦, 鲍其远, 沈宇辉, 张伟滨, 万荣. 累及髋臼的原发良性与交界性骨肿瘤的术式选择与预后评估[J]. 上海交通大学学报(医学版), 2021, 41(11): 1470-1477.

获得性囊性肾病相关肾细胞癌的研究进展

Research progress in acquired cystic disease-associated renal cell carcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

编辑推荐

Metrics